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Abstract
 
Chlamydia trachomatis {Ct.) is a Gram negative prokaryote
 
responsible for the single largest cause of infectious human
 
blindness, involving 500 million cases of trachoma worldwide,
 
and strongly implicated in genital tract infections.
 
Chlamydia trachomatis contains on its outer membrane surface
 
a variety of antigens, some eliciting a protective, others a
 
hypersensitive and detrimental immunological response. The
 
cloning, isolation, and immunogenicity of antigens in the
 
development of a chlamydial subunit vaccine is the subject of
 
this study. I have identified a 36kd Ct protein in E.coli
 
lysates, originally derived from a bacteriophage lambda
 
library. Due to low expression yields in the bacteriophage
 
vector, the Ct DNA fragment was sub-cloned into pBluescript
 
plasmid and propagated in E.coli XL-1 Blue cells.
 
The cloning, isolation, and immunogenicity of the
 
recombinant gene product were tested in 4 assays: 1) enzyme
 
restriction analysis to determine the recombinant insert
 
size, 2) dot immunoblots to screen for positive-expressing
 
recombinant clones, 3) Western immunoblots to identify the
 
recombinant chlamydial product and 4) enzyme immunoassays 
(EIA's) to determine the probable location of the 36kd 
protein in Chlamydia trachomatis. 
The results of these serological studies demonstrated
 
that: 1) the Ct recombinant protein is immunogenic for at
 
least one epitope of the 36kd Ct protein (maybe more), 2) the
 
expression of the recombinant Ct protein in pBluescript
 
increased when compared to the product yield obtained in the
 
lambda bacteriophage vector, and 3) the location of the 36kd
 
protein in Ct. remained inconclusive. Based on the results
 
obtained, further studies are necessary to clearly evaluate
 
the protective capabilities of this potential vaccine
 
canditate, and to determine its role during the growth cycle
 
of chlamydial infections.
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Introduetion
 
Chlamydia prachomatis iC%.) a major iiuman pathogen
 
responsible for a wide spectrum of diseases in both
 
industrialized ahd developing nations/ Over 4 million
 
infections of C.trachomatls in the United States, affect men,
 
women, and infants at a cost exceeding $1.4 billion dollars
 
per year in direct and indirect medical costs (21),
 
Infections caused by Chlamydla include intestinal infections
 
and diahrrea, pneumonia, urogenital infections, hepatitis,
 
and conjunctivitis (14). Chlamydiae are Gram negative
 
obligate intracellular prokaryotes which have evolved
 
morphologically distinct infectious and reproductive forms.
 
Two main structures in the chlamydial growth cycle are
 
recognized; the elementary bodies (EB) which are the
 
infectious stage of the growth cycle, and the reticulate
 
bodies (RB) which are concerned solely with the
 
multiplication of the chlamydial population within an
 
infected eukaryotic cell (4). At present only one family
 
(Chlamydiaceae) is recognized. The genus Chlamydla presently
 
contains two species, C. psittaci, and C. trachomatls , each
 
with an average genomic molecular weight of 6.0 x 10^ daltons
 
(8). The three biovars of C. trachomatls include mouse,
 
lymphogranuloma venerum (LGV), and trachoma.
 
The current classification of C. trachomatls serovars is
 
based on the antigenic differences observed using either the
 
classic micro-immunofluorescence assay (MIF) (20), or the
 
recently developed panels of enzyme-linked monoclonal
 
antibodies (5). Most strains of C.trachomatls can be
 
classified into 1 of 15 distinguishable serovars: chlamydial
 
isolates from cases of hyperendemic trachoma generally belong
 
to serotypes A, B, Ba, or C; isolates from ocular infection
 
of sexually transmitted origin or genital tract infections to
 
serotypes D to K, while LGV isolates are of serotypes LI, L2,
 
or.. L3... . ..
 
Much of what is now known about the location of various
 
epitopes on specific macromolecules has come from Western
 
immunoblot analysis of serum from humans or animals with
 
chlamydial disease, serum from immunized animals, and
 
monoclonal antibodies (3). It has been possible to identify
 
antigenic, proteins of purified EE's, representing the 15
 
serovars of C. trachomatis (13). The most prominent membrane
 
protein (60%) has a molecular weight of. 38,000-42,000
 
daltons, depending on the serotype, and is designated the
 
major outer-membrane protein (MOMP) of the chlamydial EE. In
 
addition, many other species-specific reactions have been
 
observed with a 60K outer-membrane protein, and proteins
 
ranging in molecular masses from 115K to 12 K daltons.
 
Little is known about these chlamydial proteins due to the
 
difficulty in obtaining these proteins from intact C.
 
trachomatis EE's, and the only recent applications of DNA
 
technology. However, it appears that some surface antigens
 
may regulate attachment, while others may induce
 
phagocytosis, or inhibit phagolysosomal fusion, infectivity,
 
and the host immune responses that contribute to immunity and
 
pathogenesis (14).
 
It is now apparent that of these chlamydial proteins
 
only a few are important in provoking protective immunity
 
whereas others may frequently induce hypersensitive reactions
 
which could be detrimental to the host. Thus, development of
 
a highly specific vaccine, free from competing and .non­
essential , components will require the identification and
 
isolation of a single protective immunogenic determinant.
 
(23). Early trials with conventional vaccines against C.
 
trachomatis consisting of inactivated and purified EE's in
 
both nonhuman primates and human populations have resulted in
 
both short-lived protective immune responses and, detrimental
 
hypersensitive reactions in the hosts (10). A murine model
 
of C. trachomatls (Ct.) genital tract infection (GTI) has
 
been developed by innoculating progesterone-treated female
 
mice intravaginally with human oculogenital isolates of Ct.
 
(9). Ito et al. has determined that homologous protection
 
occurs against Ct GTI following systemic immunization of CF-1
 
mice with formalin-killed (FK) Ct. serovar H. Immunization
 
with serovar D provides heterologous protection. Currently,
 
there , are no commercially available vaccines. However,
 
recombinant DNA techniques have been employed to clone
 
chlamydial DNA coding for MOMP and other C. trachomatls
 
proteins into Escherichia coll expression vectors (16). The
 
cloning and isolation of antigens as an alternative route in
 
the development of a subunit vaccine against C. trachomatls
 
is the subject of this study.
 
This study involves the identification of a
 
bacteriophage-derived 36 KD chlamydial recombinant component
 
from serovar D by Western immunoblots. An immunoreactive
 
band of approximately 36KD has been identified in the
 
recombinant clone and the Ct. serovar D antigen preparations,
 
and is absent in the parent (non-insert containing) lambda
 
vector; the prospect that this 36KD protein may be related to
 
the 30KD Ct. protein involved in mediating attachment to host
 
cells, emphasizes the significance of this recombinant gene
 
product.
 
The biological relevance of this 36KD protein and other
 
chlamydial antigens has prompted efforts to utilize molecular
 
genetic approaches to prepare quantities of defined
 
chlamydial antigens in an Escherichia coll expression
 
system. The low yield of expression in initial experiments
 
with EMBL-3 prompted the use of the pBluescript expression
 
vector. Relatedness between this recombinant component and
 
the analogous chlamydial component obtained from EB's was
 
determined by serological assays, following the successful
 
 sub-cloning of the Ct gene fragment into pBluescript. The
 
specific aim was to determine the immunogenicity of an HPLC-

purified recombinant chlamydial protein by Western
 
immunoblots. In addition, DNA sequencing and enzyme immuno­
assays may provide insights into the structural and
 
functional mechanisms of this recombinant gene. The
 
likelihood of this recombinant Ct. protein becoming a
 
candidate for vaccine development is discussed.
 
Materials and Methods
 
Animals.Outbred Cf-1 female mice > 8 weeks old (Charles
 
River Breeding Lab.; Willmington, MA.) were used for
 
immunogenicity studies.
 
Bacteria. A single strain of E. coll LE 392-P2 and E. coll
 
XL-1 Blue (rec A~, lac", end Al, gyr A96, thi, hsd R17, sup
 
E44, rel Al, {P'proAB, lac jQ, lac ZM15, TnlO (Tet^)}
 
(Strategene, San Diego, CA.) were used as hosts for
 
recombinant cloning.
 
Plasmid. pBluescript KS (+/-) is a 2,964 basepair phagemid
 
derived from pUC19. The vector possesses an fl phage origin,
 
a Col El origin, and T3 and T7 promoters flanking a
 
polylinker region containing 21 unique restriction sites.
 
pBluescript also contains a lac Z promoter for blue/white
 
color selection or fusion protein induction with IPTG and
 
provides ampicillin resistant colonies (Strategene, San
 
Diego, CA.).
 
Bacteriophage. Lambda phage EMBL-3, a derivative of
 
lambda 1059 (Promega Biotech., CA.), was used to clone and
 
amplify recombinant Ct. lambda clones.
 
Antisera. Polyclonal antiserum to C. trachomatis was 
obtained from systemically (sub-cutaneous) immunized mice 
with purified Ct serotype D. 
Preparation of E. coli LE 392-P2 and Recombinant
 
Bacteriophage Lambda EMBL-3 stocks.
 
Escherlchia coll LE 392-P2 cultures were established in NCZ
 
broth, consisting of NZ amine, NaCl, casamino acids, bacto­
yeast extract, MgS04 • 7H2O, pH 7.5 (Gibco Laboratories;
 
Madison, WI.), with 0.2% maltose, and incubated overnight at
 
37° C with moderate agitation. Fbllowing the incubation
 
period, the cultures were centrifuged at 2,772.2 X g for 20
 
minutes at 4°C (Sorvall RT 6000 refrigerated centrifuge;
 
DuPont Instruments) and the pellet fraction resuspended in
 
half the original volume in SM media (NaCl, MgS04 • 7H20, IM
 
Tris-Cl, pH 7.5) (11).
 
Maximum yield of plate lysate stocks was assured by
 
infecting 0.1 ml of plating bacteria with 10^ EMBL-3 lambda
 
bacteriophage particles. Plating bacteria (0.1 ml) were pre­
incubated with 10^ bacteriophages at 37°C for 30 minutes, and
 
then combined with 3 ml of melted top agar (1.5%) and poured
 
over bottom agar (2.0%). The plates (150 x 15 mm) were
 
incubated overnight at 37°C. The soft agar of confluently
 
lysed plates was scraped into sterile centrifuge tubes; 5 ml
 
of SM media and 0.1 ml of chloroform were added to the tubes,
 
and the above mixture was incubated for 15 minutes at 37°C
 
under continuous shaking. Following the incubation period,
 
the mixture was centrifuged at 2,772 X g for 20 minutes at
 
4°C, and the supernatant (recombinant) recovered. The
 
recombinant bacteriophage stock was titered to approximately
 
a final concentration 1.0 x 10^'^/ml, and stored at 4°C after
 
adding chloroform to 0.3%.
 
Screening of Recombinant Lambda EMBL-3 Bacteriophage.
 
Escherlchia coll LE 392-P2 overnight culture was infected
 
with recombinant phage preparation at a 10:1 multiplicity of
 
infection (M.O.I.)f and incubated at 37®C for 75 to 80
 
minutes with strong agitation. The E. coll lysate was
 
collected and centrifuged for 20 minutes at 2772.2 x g.
 
Whole lysate, pellet, supernatant fractions along with the
 
appropriate controls {E. coll LE-^392-P2, Lambda EMBL-3
 
bacteriophage, and Ct. serovar D whole cell suspension) were
 
dot blotted onto nitrocellulose membranes (Bio-Rad
 
laboratories; Richmond, CA.). Membranes were immersed into a
 
blocking solution (1% gelatin, 1% BSA in TTBS [Tween-20 Tris
 
buffered saline, pH 7.5]) for 30 to 45 minutes and washed in
 
TTBS twice at room temperature.
 
The nitrocellulose membranes were incubated with mouse
 
anti-serovar D {E. coll absorbed) polyclonal antibody diluted
 
1:200 in Tris buffered saline containing 0.05% Tween-20, 1%
 
BSA, 1% gelatin, and 0.01% Thimerosal overnight at room
 
temperature. Membranes were washed for 10 minutes in TTBS
 
washing solution and incubated with peroxidase-conjugated
 
goat anti-mouse IgG antibody (1:3,000) for one hour at room
 
temperature. The membranes were then washed twice for ten
 
minutes, and a final wash with TBS was applied to remove
 
Tween-20 residues which affect the color development
 
reaction. The immune reactions were detected by adding a
 
solution containing 0.5mg of 4-chloro-l-naphthol per ml and
 
0.015% H2O2 in TBS and agitated for 45 minutes. Double
 
distilled water was added to stop the color reaction.
 
Subcloning of Recombinant Ct gene fragment from
 
bacteriophage Lambda EMBL-3 to pBluescript KS (+).
 
i. Purification and Extraction of EMBL-3 DNA.
 
Lambda EMBL-3 bacteriophage DNA was concentrated and purified
 
by cesium chloride gradient centrifugation. An equal volume
 
of chloroform was added to 25 ml of the recombinant EMBL-3
 
bacteriophage stock and vortexed for 30 seconds. The organic
 
and aqueous phases were separated by centrifugation at 1600g
 
for 15 minutes at 4°C. The aqueous phase containing the
 
recombinant bacteriophage was collected and 0.5g/ml of solid
 
ultra-pure cesium chloride (Sigma, St. Louis, MO.) was added
 
and mixed gently. After the cesium chloride was dissolved,
 
the recombinant bacteriophage suspension- was carefully
 
layered onto cesium chloride step gradients in decreasing
 
density ( 1.7 g/ml, 1.50 g/ml, 1.45 g/ml, and 1.15 g/ml) in
 
cellulose nitrate centrifuge tubes. The mixture was
 
centrifuged in a Beckman SW 41 rotor at approximately 80,000
 
X g for 2 hours at 4*^C. The bacteriophage formed a visible
 
band between the 1.45 g/ml and 1.50 g/ml cesium chloride
 
layers. The recombinant bacteriophage particles were drawn
 
from the cellulose nitrate tube by puncturing the side of the
 
tube with a 21 gauge needle. Cesium chloride (1.5 g/ml in
 
SM) was added to the recovered recombinant bacteriophage
 
suspension to fill another cellulose nitrate tube and the
 
suspension was centrifuged at 150,000 x g for 24 hours at 4®C
 
in a Beckman Type-50Ti rotor. The band of bacteriophage
 
particles was collected a second time as described above and 
stored in CsCl at 4°C. 
The cesium chloride was removed from the purified 
recombinant bacteriophage preparation by dialysis at room
 
temperature for 1 hour against a 1000:fold volume excess of
 
dialysis buffer (lOmM NaCl, 50mM Tris-Cl pH 8.0, and lOmM
 
MgCl2 )• After addition of EDTA (final concentration of
 
20mM), pronase (final concentration 0.50 mg/ml), and SDS
 
(0.5% final concentration), the dialysis tube was inverted
 
several times and incubated for an additional hour at 37°C.
 
The bacteriophage DNA was extracted with an equal volume of
 
phenol and centrifuged at 1600 x g for 5 minutes at room
 
temperature. A second extraction of the aqueous phase was
 
done with a 50:50 mixture of phenol and chloroform. A third
 
and final extraction of the aqueous phase was performed with
 
an equal volume of chloroform. The final aqueous phase was
 
dialyzed once more in three 1000:fold volume of TE buffer
 
(lOmM Tris-Cl pH 8.0 and ImM EDTA) at 4^0 overnight.
 
ii. Enzyme Restriction Analysis o£ EMBL-3 DNA.
 
Recombinant lambda EMBL-3 DNA (1 ug) was digested with 5U/ul
 
of ECO-RI (Bethesda Research Laboratories and Life
 
Technologies, Inc., Gaithersburg, MD.) , and 5U/ul of SAL-I
 
(BRL, Inc., MD.) individually in the presence of lOX buffer
 
#3 (50mM NaCl, lOmM Tris-Cl pH 7.5, lOmM MgCl2, ImM
 
dithiothreitol) and sterile double distilled water (ddH20) at
 
37°C for 1 to 1.5 hours. One tenth of the digested DNA
 
mixture was analyzed by 0.8% agarose gel (Sigma, St. Louis,
 
MO.) electrophoresis, and stained with ethidium bromide
 
(lOmg/ml stock ; Sigma, St. Louis, MO. ) . The remaining
 
DNA mixture was phenol/chloroform extracted once, and the
 
aqueous layer was treated with 1/4 volume of NH4OAC (lOM)
 
and two volumes of cold 95% ethanol. The DNA preparation was
 
precipitated overnight at -20°C , and centrifuged at 20,000
 
X g for 30 minutes at room temperature. The pellet was
 
washed in 70% ethanol and centrifuged for 5 minutes at 20,000
 
X g. The supernatant fraction was discarded and the pellet
 
was lyophilized.
 
ill. pBluescript plasmid DNA 5' end dephosphorylation
 
procedure. pBluescript plasmid (10 ug) previously digested
 
with respective restriction enzymes ECO-RI and SAL I was
 
extracted once with equal volumes of phenol/chloroform,
 
precipitated with ethanol, and treated with calf intestinal
 
alkaline phosphatase (CIP) (Boehringer Mannheim Biochemicals,
 
Indianapolis, ID.) to minimize self-ligation of the plasmid
 
vector.
 
The digested and purified pBluescript DNA mixture
 
obtained from the above procedure was dissolved in lOmM Tris­
C1 (pH 8.0). The amount of calf intestinal alkaline
 
phosphatase (CIP) used to remove the terminal phosphates from
 
the 5'ends of the digested 3Kb pBluescript vector took into
 
account: 1) the number (pmoles) of 5' ends to be
 
dephosphorylated, 2) the size of the DNA fragment (SKbase),
 
and 3) the amount of DNA available (lOug). Five microliters
 
of lOX CIP buffer (0.5 M Tris-Cl pH 9.0, 10 mM MgCl2, ImM
 
ZnCl2r lOmM spermidine), sterile water, and 0.083 units of
 
CIP {1 ul} were added to the dissolved plasmid DNA, and the
 
50 ul total reaction mixture was incubated at 37°C for 30
 
minutes, after which a second aliquot of CIP was added to the
 
solution and incubated for an additional 30 minutes.
 
Inactivation of CIP was accomplished by adding to the
 
reaction mixture nitrilotriacetic acid to a lOmM
 
concentration and incubating at 65°C for 45 minutes. The
 
plasmid DNA was extracted twice with equal volume of
 
phenol/chloroform and twice with chloroform, precipitated
 
with 95% ethanol at -20°C, and lyophilized.
 
iv. Ligation of Lambda-derived Ct DNA fragment to
 
pBluescript plasmid, and Calcium Chloride
 
transformation. The EMBL-3 DNA lyophilized pellet obtained
 
from the enzyme restriction procedure described above was
 
resuspended in 10 ul of sterile dd H2O, and an aliquot (2 ul)
 
ligated to the CIP treated plasmid vector. The ligation
 
reaction mixture consisted of sterile ddH20, complementary
 
digested CIP-treated pBluescript vector, lOX ligase buffer
 
(0.6M Tris—C1 pH 7.6, 50mM Mg CI2, 50mM dithiothreitol, ATP)
 
and T4 DNA ligase (10 units/ul) (Strategene, San Diego, CA.)
 
in a 10 ul volume. The reaction mixture was briefly
 
centrifuged and incubated at 4°C overnight.
 
Escherichia coll strain XL-1 Blue cell cultures were
 
grown to log phase. The bacterial cell suspension was
 
concentrated by centrifugation (2,272 x g, at 4*^0 and
 
resuspended in half of the original culture volume of an ice-

cold, sterile solution of 50mM CaCl2 and lOmM Tris-Cl (pH
 
8.0). The cell Cultures were chilled for 15 minutes and then
 
centrifuged at 2,272 x g for 5 minutes at 4'^C. The
 
supernatant was discarded and, the pellet was resuspended in
 
1/15 of the original volume of an ice-cold solution of 50mM
 
CaC12 and lOmM Tris-Cl (pH 8.0). Ten nanograms of ligated
 
recombinant DNA in a volume of 10 to 25 ul were aliquoted
 
into 15-ml sterile, round-bottom test tubes, and 100 ul of
 
competent E. coll strain XLl-Blue cells were added to each
 
test tube. The tubes were gently swirled to mix, then placed
 
on ice for 30 minutes. The cells were heat shocked at 43°C
 
for 3 minutes, 0.8 ml of 2x YT media added (16 g
 
bactotryptone, 10 g NaCl, 10 g Yeast extract, 1 liter ddH20,
 
pH 7.3) , and incubated for 1 hour at 37®C. Transformed cells
 
were spread onto plates containing ampicillin (100 ug/ml;
 
BMB, Indianapolis, ID.), tetracycline (12.5 ug/ml; Sigma,
 
MO.), 40ug/ml X-Gal (BMB), and 5mM Isopropyl-B-D­
thiogalactopyranoside (IPTG; Five prime to three prime. Inc.,
 
Westchester, PA.), and incubated overnight at 37°C.
 
Plasmid Sizing and Screening of Recombinant Colonies.
 
Each millimeter diameter white recombinant colony was
 
transferred to a tube containing 5 ul of protoplast buffer
 
solution (30 mM Tris pH 8.0, 5 mM EDTA, 50 mM NaCl, 20%
 
sucrose, 50 ug/ml RNA'se A (BRL, MA.), and 50 ug/ml lysozyme
 
(Sigma, MO.), and mixed rapidly by twirling a wire loop in
 
the solution. Each suspension was streaked onto a master
 
plate for recovery. Two microliters of lysis buffer (Tris­
acetate electrophoresis buffer, 2% SDS, 5% sucrose, and 0.04%
 
Bromophenol blue) were added into the wells of a 0.8% agarose
 
gel. The samples were then loaded into the wells,
 
electrophoresed (50-100V/lh.), stained with ethidium bromide,
 
and photographed.
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Prospective recombinant and non-insert containing
 
colonies were selected and grown in 50 ml of LB media (pH
 
7.5) (Gibco; Madison, WI.) containing ampicillin (75 ug/ml)
 
at 37°C overnight. Bacterial cultures were,diluted to early
 
log phase and then incubated for 2-3 hours to early log phase
 
at 37®C. At this point in the growth curve of the cell
 
cultures, IPTG to a final concentration of 5mM was added and
 
newly induced cells were incubated for an additional 3 hours
 
or until cell cultures reached early stationary phase. IPTG
 
induced cultures were concentrated 50X by centrifugation
 
(3000 X g) and lysed by sonication at setting 3(Biosbnic, III>
 
Bronwill Scientific; Rochester, N.Y.), Samples were
 
centrifuged at 12,400 X g (Beckman microfuge 12) for 15
 
minutes; supernatant and pellet fractions were collected, and
 
screened by dot-immunoblots for product expression.
 
Recombinant pBluescript Isolation for DNA Sequencing.
 
A 50 ml recombinant cell culture was grown overnight in LB
 
Media under ampicillin selective conditions at 37°C. The
 
culture was centrifuged at 4000 rpm (~3000 x g) for 15
 
minutes in a J6B centrifuge. The pellet fraction was
 
resuspended in 3.3 ml of lysis buffer (50 itiM glucose, 25mM
 
Tris-Cl pH 8.0, lOmM EDTA, 4 mg/ml lysozyme). The lysozyme
 
was added to the buffer just prior to use and the cell
 
suspension was incubated at room temperature for 5 minutes;
 
6.6 ml of 0.2 M NaOH, 1% SDS was added, mixed gently, and
 
incubated on ice for another 5 minutes. The cells were
 
incubated for an additional 5 minutes on ice following the
 
addition of 5 ml of 5M potassium acetate. The lysate mixture
 
was centrifuged for 15 minutes at 4000 rpm. The suspernatant
 
fraction was collected and placed in a 50 ml sterile
 
centrifuge tube, and extracted with an equal volume of phenol
 
for 5 minutes. The top aqueous phase (plasmid DNA) was
 
recovered and placed into another sterile 50 ml centrifuge
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tube, two volumes of 95% ethanol were added and the
 
suspension incubated for 3 minutes at room temperature. The
 
plasmid DNA preparation was centrifuged for 20 minutes at
 
4000 rpm, rinsed with 70% ethanol and dried in a speed vac
 
concentrator (Speed Vac SVCIOOH, Savant Instruments, Inc.,
 
Farmingdale, NY.). The dried DNA preparation was then
 
dissolved in 1.6 ml TE buffer; 50 ul of RNAse was (1 mg/ml
 
pancreatic RNAse) added and the suspension incubated for 30
 
minutes at 37°C. One milliliter of 20% polyethylene glycol
 
(PEG) 8000, 2.5 M NaCl was added and the suspension incubated
 
on ice for an additional 45 minutes. The plasmid preparation
 
was then centrifuged for 20 minutes at 4000 rpm and the
 
pellet was rinsed with 70% ethanol to remove PEG and
 
submitted to a speed vac drying. A volume of 200 ul of TE
 
buffer was added and the plasmid DNA concentration was
 
determined at 260nm (Spectrophotometer 2000).
 
Denaturatlon of Double Stranded pBluescript and BSl
 
Recombinant DNA for Sequencing. Supercoiled plasmid DNA
 
(3.5-5 ug) was dissolved in 18 ul of sterile ddH20. A volume
 
of 2 ul of 2M NaOH was added to the dissolved DNA and
 
incubated for 5 minutes at room temperature. This was
 
followed by the addition of 8 ul of 5M ammonium acetate (pH
 
7.4), and 100 ul of 95% ethanol, and an incubation for 15
 
minutes at -70®C. The denatured DNA sample was centrifuged
 
for 15 to 30 minutes at 14,000 x g. After carefully removing
 
and discarding the supernatant, the pellet was dried in a
 
speed vac.
 
DNA Sequencing of pBluescript DNA template with T7
 
DNA Polymerase. A modification of the chain-termination
 
DNA sequencing method originally described by Sanger, et al.
 
(2) was utilized to sequence the recombinant plasmid DNA
 
samples. Briefly, the chain-termination method involved the
 
12
 
synthesis of a DNA strand by a DNA polymerase In vitro using
 
a single-stranded DNA template. Synthesis was initiated at
 
only one site where an oligonucleotide primer annealed to the
 
template. After denaturation of the pBluescript plasmid DNA
 
(5 ug) with 2N NaOH, a synthetic oligonucleotide primer was
 
annealed to the template DNA. , The pBluescript vector
 
contains 3 different primer-annealing sites on either side of
 
the multiple cloning region of the double stranded plasmid
 
DNA: M 13 -20 primer (5'GTAAAACGACGGCCAGT 3' —>), T7 primer
 
<5* AATACGACTCACTATAG 3'—>), SK primer (5' TCTAGAACTAGTGGATC
 
3'—>), KS primer (<—3' GCTATGGCAGCTGGAGC 5'), T3 primer (
 
<—3'GAAATCACTCCCAATTA 5'), and Reverse primer (<-­
3'GTACCAGTATCGACAA 5') (Molecular Genetics Laboratories, City
 
of Hope, OA.). The synthesis reaction was terminated by the
 
incorporation of a nucleotide analog that will not support
 
continued DNA elongation. A radioactively labeled nucleotide
 
(35s) was also included in the synthesis, so that the
 
labelsd chains of various lengths could be visualized by
 
autoradiography after separation by high-resolution
 
electrophpresis.
 
The molar ratio of synthetic oligonucleotide primer to
 
template was adjusted to 1:1. The concentration of the
 
primer solution was adjusted so that 1 ul contained the mass
 
of primer needed to achieve the desired primer:template
 
ratio. The denatured template DNA (5 ug) was resuspended in
 
7 ul of sterile H2O, then 2 ul of annealing buffer (200mM
 
Tris-HCl pH 7.5, 100 mM MgCl2, 250mM NaCl), and 1 ul of
 
synthetic oligonucleotide primer solution (50 ng/ul) were
 
added. The subsequent annealing reaction was incubated at
 
65°C for 2 minutes, and then allowed to cool slowly to room
 
temperature over a period of about 30 minutes. The following
 
were added to the annealed template-primer: 1 ul of
 
dithiothreitol (DTT, 0.IM), 2 ul of labeling nucleotide mix
 
(1.5uM dGTP, 1.5uM dCTP, 1.5uM dTTP), 5 uCi alpha-^^s dATP
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 (>1000 mCi/mmol) (New England Nuclear, Wilmington, DE), and 3
 
units of T7 DNA polymerase to a total volume of approximately
 
15 ul. The labeling solution was mixed thoroughly and
 
incubated for 5 minutes at room tefflperature.
 
Four tubes labeled "G", "A", "T", "C", were filled each
 
with 2.5 ul of the appropriate dideoxy termination mixture,
 
and pre-warmed to 37°C. The dideoxy termination mix
 
consisted of a mixture of 80uM dGTP, 80uM dATP, 80uM dTTP,
 
and dCTP; in addition, the "G" mixture contained 8uM
 
dideoxy-dGTP; the "A" mix, 8uM ddATP; the "T" mix, 8uM ddTTP;
 
and the "0" 8uM ddCTP. Following the labeling reaction, 3.5
 
ul of labeling suspension was transferred to each
 
corresponding dideoxy termination tube, labeled either "A",
 
"G", "G", or "T". After a 2-5 minute incubation at 37°C, 4
 
ul of Stop solution (95% Formamide, 20mM EDTA, 0.05%
 
bromophenol blue, and 0.05% Xylene Cyanol FF) were added to
 
each termination reaction; and the suspension was mixed and
 
stored at -20^0.
 
i. Sequencing Gel Electrophoresis
 
The glass plates (60cm long) were cleaned with soap,
 
rinsed thoroughly with water, dried, and rinsed with ethanol
 
and dried once again. The notched plate was treated with a
 
10% organo-silane (silicone) solution (Prosil-28, PGR Inc.,
 
Gainesville, F1.), rinsed with distilled water and dried.
 
The glass plates were arranged for assembly, with the
 
silicone-treated plate facing inward. Two 0.4 mm side
 
spacers (BRL, Gaithersburg, MA.) were placed between the long
 
edges of the plates. An extra piece of the same material was
 
inserted at the bottom of the plate sandwich, and the plates
 
were clamped together.
 
The 6% acrylamide gel was prepaired to a final volume of
 
50 ml by combining 20 ml of 20% acrylamide solution, 5 ml of
 
lOX TBE buffer (108 g Tris base, 55 g Boric acid, 9;3 g EDTA/
 
1 liter, pH. 8.3), and 25 ml of 46% Urea solution (Bio-Rad
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Laboratories, Richmond, CA.). The acrylamide mixture was
 
filtered and degased under low vacuum for 5 minutes. Gel
 
formation was initiated by adding 250 ul of 10% ammonium
 
persulfate and 50 ul of TEMED [N,N,N',N'-Tetramethy1­
ethylenediamine] to the acrylamide mixture and swirled to
 
mix. The final solution was immediately poured into a 50 ml
 
syringe while blocking the tip. The plunger was inserted
 
into the syringe, air ejected, and the solution was injected
 
between the plates (set at a 45° angle), slowly to avoid
 
introducing air bubbles.
 
After pouring the gel, the plates were laid in a
 
horizontal position, the surface-former of a shark-tooth comb
 
inserted, and the gel allowed to polymerize for ~ 2 hours.
 
The comb was removed and the formed surface was rinsed with
 
distilled water, to remove unpolymerised acrylamide. The gel
 
was then placed in the electrophoresis apparatus (BRL,
 
Bethesda, MD.), and IX TBE buffer was added to the buffer
 
chambers. The gel was pre-ran at 70 watts (constant) for
 
approximately 30 minutes. Prior to loading the samples, the
 
power supply was switched off and the shark-tooth comb was
 
inserted, so that the points just touch the surface of the
 
gel. The samples were then heated to 75°C for 2 minutes and
 
1.5 ul were loaded in each lane. The power supply was
 
reconnected and the samples were electrophoresed at 55-60W
 
for approximately 90-120 minutes.
 
ii. Autoradiography
 
After removing the gel/plate assembly from the
 
electrophoresis apparatus, the assembly was laid in a
 
horizontal position with the notched plate uppermost and the
 
plates were carefully separated so that the gel remained
 
attached to one of them. The gel was then transferred to a
 
supporting sheet of filter paper (Whatman #1), covered with
 
Saran plastic wrap, and dried using a vacuum gel dryer. When
 
the gel was dried, the plastic wrap was removed and the gel
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was transferred to a film cassette. A sheet of X-ray film
 
(Kodak Diagnostic Film, 35 x 43 cm, Eastman Kodak, Rochester,
 
N.Y.) was placed on the gel, and exposed in the dark
 
overnight at room temperature. The film was developed
 
according to the manufacturer's instructions.
 
Analysis of Recombinant Gene Product by SDS-PAGE
 
Electrophoresis. A Bicinchoninic acid protein assay (BCA)
 
(Pierce, Rockford, II.) was first performed to determine the
 
protein concentration of the lysate samples. A series of
 
calibration protein standards was prepared by 2-fold serial
 
dilutions of 1.0 mg/ml Bovine Serum Albumin (BSA) stock
 
stahdard to a final standard concentration of 63 ug/ml in PBS
 
diluent buffer. An aliquot of 0.1 ml of each standard
 
dilution and unknown protein sample were placed into
 
appropriately labeled tubes; blanks obtained 0.1 ml of
 
diluent buffer. To each tube, 2.0 ml of "working reagent"
 
(50 parts of Reagent A with 1 part of Reagent B) were added
 
and mixed well.
 
The tubes were incubated at 60®C for 30 minutes. After
 
allowing the tubes to cool to room temperature, the
 
absorbance of each tube was measured at 562nm. A standard
 
curve was prepared by plotting absorbance at 562nm against
 
protein concentration. From this standard curve, the protein
 
concentration for each unknown lysate protein sample was
 
determined. Based on the protein concentration of each
 
lysate sample, dilutions were performed to standarize all
 
samples to a final gel loading concentration of approximately
 
1.0 mg/ml.
 
. i. Gel Preparation
 
The plates were soaked in 1:1 HNO3/ H2O for 3 hours,
 
rinsed with distilled water, and allowed to air dry. The
 
running gel (12.5% acrylamide:0.011% Bis-acrylamide, 0.375M
 
Tris-Cl pH 8.8, 0.1% SDS, ddH20) and the stacking gel (5%
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acrylamide:0.001% Bis-acrylamide, 0.125M Tris Gi pH 6.8, 0.1%
 
SDS, ddH20) were prepared and de-gased with a moderate
 
vacuum. The plates were aligned and assembled in a casting
 
stand (Protean II Slab cell, Bio-Rad, Richmond, . OA.)
 
according to the manufacturer's instructions. Prior to
 
pouring the running gel, 15 ul TEMED and 150 ul of freshly
 
made 10% ammonium persulfate (AP) were added to the
 
acrylamide solution. An anaerobic environment was produced
 
for gel polymerization by an overlay of a 0.1% SDS solution.
 
The gel was allowed to polymerize for approximately 30
 
minutes. The overlay solution was poured off and the gel was
 
rinsed three times with the 0.1% SDS solution.
 
The stacking gel was then poured, adding the TEMED and
 
10% AP just prior to pouring. The well-forming comb was
 
appropriately placed, and the gel was allowed to polymerize
 
for 20 minutes. The comb was removed and the wells were
 
washed 3 times with running buffer ( 25mM Tris, 192mM
 
glycine, 0.1%SDS pH 8.3). The plate-sandwiched gel was
 
assembled in the cooling core unit. The sample specimens
 
were diluted 1:1 in 2X sample buffer (O.lmM Tris-Cl pH 6.8,
 
2.5% SDS, 5.0% B-Mercaptoethanol, 20% glycerol, ddH20), and
 
boiled for 5 minutes. Approximately 50 ul of each protein
 
sample were loaded into each well. The cooling-core unit
 
with the glass plate sandwiched gel was placed in the
 
electrophoresis buffer chamber. Running buffer was placed in
 
the lower and top chamber. To the running buffer in the top
 
chamber, 500 ul of 0.1% bromophenol blue dye were added and
 
the gel was electrophoresed at a constant power of 3 watts
 
for 4 to 5 hours.
 
ii. Western Blot
 
Once the electrophoretic run was completed, the power
 
supply was turned off, and the plates were removed from the
 
electrophoresis chamber. The plates were carefully pried
 
open, and the gel was appropriately marked, and stabilized by
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immersing it in transfer buffer (25mM Tris, 192mM glycine,
 
20% methanol) for 10 minutes. One sheet of nitrocellulose
 
membrane and four sheets of absorbent filter paper (Whatman
 
3MM) were cut to the size of the gel, and soaked in transfer
 
buffer. The gel, nitrocellulose, filter papers, and support
 
pads, immersed in transfer buffer, were assembled to form a
 
gel/membrane sandwich/ keeping all the components wet and
 
making sure the sandwich was tightly assembled, to exclude
 
air bubbles. The complete sandwich was placed in the
 
transfer tank with the membrane closest to the positive
 
electrode. The electro-transfer was carried out at lOOV for
 
2 hours. After transfer, the power supply was disconnected,
 
and the gel/membrane sandwich was disassembled. The gel was
 
then stained with Coomassie brilliant blue R-250 (0.1%
 
COomassie blue R-250, 46% methanol, 8% acetic acid) for 20
 
minutes, destained overnight in 20% methanol, 8% glacial
 
acetic acid, at room temperature, and finally dried using a
 
vacuum gel drier. The nitrocellulose sheet was treated
 
according to Bio-Rad's Immuno-Blot^"^ enzyme immunoassay for
 
the detection of reactive proteins (Bio-Rad, Richmond, CA.).
 
Bovine serum albumin (1.0%) and gelatin (1.0%) were used as
 
blockers. Bound antigen was then incubated with polyclonal
 
CT serovar D antibodies. The membrane was washed to remove
 
unbound antibody, and then incubated with GAM-HRP and washed
 
again. Horseradish peroxidase substrate color development
 
completed the procedure.
 
Protein Purification by Size Exclusion HPLC. The
 
liquid chromatograph was assembled from a Waters Millipore M­
45 solvent delivery system ( Waters Instruments, Milford,
 
MA.), a Waters Associates Model 441 absorbance detector
 
(Waters Instruments, MA.), and a Model U6K universal liquid
 
chromatograph injector (Waters Instruments, MA.). A Bio-sil
 
TSK-250 (Bio-Rad, CA.) HPLC gel filtration column, having a
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mean particle diameter of lOum and 300 x 7.5mm I.D. was used.
 
The supernatant fraction from positive IPTG induced
 
recombinant lysates was collected, and 0.3 ml of the protein
 
solution were injected into the HPLC system. The mobile
 
phase, consiting of IX phosphate buffer saline (PBS), was set
 
to a flow rate of 0.300 ml/min., and the ultraviolet
 
absorbance detection was adjusted to a wavelength of 280 nm.
 
The fractions were collected and screened for immunoreactive
 
proteins.
 
Immunizations. Twenty-one CF-1 female mice, separated into
 
7 different groups, were immunized with the following antigen
 
preparations: (1) Pellet fraction from recombinant lambda
 
EMBL-3 bacteriophage-derived lysate (containing the Ct gene),
 
(2) pellet fraction from parent bacteriophage strain lysate
 
(EMBL-3), (3) Supernatant fraction from subcloned recombinant
 
pBluescript KS derived lysate (pBS-l), (4) supernatant
 
fraction from parent plasmid strain lysate (pBluescript), (5)
 
HPLC-purified pBS-1 lysate preparation, (6) formalin-killed
 
Chlamydla trachomatis Serovar D, and (7) control group (non­
immunized). Each group of animals was injected
 
subcutaneously on each of two occassions (14 days apart) with
 
suspensions (100 ul in PBS) containing 200 ug of total
 
protein.
 
Two weeks after the second inoculation, the mice were
 
CO2 euthanized and exsanguinated. The blood samples were
 
allowed to clot for 30 to 60 minutes at 37°C. The clot was
 
then separated from the sides of the collection vessel; and
 
the serum was removed from the clot by centrifuging at 10,000
 
X g for 15 minutes at 4<^C. The serum was stored at -20°C.
 
Enzyme Immunoassay (EIA). Renografin purified, SDS
 
solubilized and whole cell chlamydial antigen (serovar D)
 
were diluted 1:500 and 1:1000 with 0.05M carbonate buffer
 
19
 
(pH. ;9.6). In microtlter plat:es/ 70 ul; of each diluted
 
antigen were dispensed per well, allowing the antigen to
 
adsorb onto the bottom of each well for 3 days at 4®C. After
 
allowing the microtiter plates to come to room temperature,
 
the antigen excess was washed off 3 times with washing
 
soiution ,(1X PBS/ 0.05% Tweeh ^^^ and blotted dry.
 
An aliquot of 0.2 ml of buffer G (lOX PBS, 0.OlM MgCl2,
 
1% BSA, 5% gelatin, ddH20) was dispensed into each well and
 
incubated for 30 minutes at 37®C in a 10% CO2, humidified
 
incubator. The microtiter plates were washed again 3 times
 
with washing solution and blotted dry. The serum against
 
each group of antigen preparation from the immunization
 
procedure described above, was diluted 1:100 and 1:500 with
 
buffer G. Each dilution was dispensed into separate wells.
 
The serum was incubated for 1 hour at 37°C in a CO2,
 
humidified incubator. Plates were washed 3 times to remove
 
serum and blotted dry. Seventy microliters of a 1:2000
 
dilution of HRP-GAM IgG antibodies were aliquoted into each
 
well and incubated for 1 hour at 37°C.
 
Excess conjugate was removed with 3 rinses of IX PBS
 
/0.05% Tween 20, blotted dry, and 70 ul of 0.4 mg/ml ortho­
phenylenediamine in phosphate citrate buffer (0.2M Na2HP04,
 
0.1 M citrate, ddH2Q, 30% H2O2, pH 5.0) were added per well.
 
The plates were incubated for 30 minutes in the dark at room
 
temperature. The color development reaction was stopped by
 
adding 50ul of 2.5M H2SO4 per well, and the absorbance read
 
at 490nm. '
 
Results
 
The original low yield of recombinant product (CT-9)
 
obtained from the bacteriophage lambda EMBL-3 lysates
 
necessitated an examination of all the factors influencing
 
bacterial cell growth and bacteriophage infection.
 
Parameters tested included MOT, bacterial concentration.
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media, cell toxicity, and aeration. The following results
 
identify the combination that supported maximum product
 
yield.
 
Bacterial cultures of 8.0 X 10® cells/ml were infected
 
at an M.O.I of 10:1 of a bacteriophage to bacterial cell,
 
where the efficency of phage attachment ranged between 80 to
 
90%. Thirty minutes after phage adsorption, the cell
 
cultures were vigorously agitated, and visible lysis was
 
apparent 75-90 minutes after initial infection. The cell
 
lysate was collected, centrifuged, and the pellet and
 
supernatant fractions were tested for a Ct product signal by
 
dot immunoblots; most of the Ct product signal was found to
 
be associated with the pellet fraction. Figure 1 compares
 
the level of immunoreactive signal obtained from the
 
supernatant and pellet fractions. Two-fold serial dilutions
 
from each fraction confirmed the association of the
 
recombinant product with the pellet fraction, despite some
 
remaining product in the supernatant fraction. Aeration was
 
examined as a means of influencing the virulent nature of
 
EMBL—3'S bacteriophage lytic cycle, thus providing a means to
 
increase the yield of recombinant product. The effect of
 
aeration during bacteriophage infection was determined by
 
establishing cell cultures, infecting them with equal
 
M.d.I.'s, and incubating either statically or with moderate
 
aeration. Only a slight increase in Ct product signal was
 
evident in the statically incubated cultures when compared to
 
aerated cultures, despite a 50-fold pellet concentration
 
(Figure 2).
 
Low expression yields in the EMBL-3 bacteriophage vector
 
prompted efforts to subclone the recombinant chlamydial
 
insert into a high expression vector (pBluescript) featuring
 
better selection, and induction control.
 
Subcloning of Recombinant Bacteriophage Lambda
 
EMBL-3 to pBluescript Plasmid. Isolated and purified
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reconibiriant EMBL—3 DNA samples (CT—9) were cleaved with Eco
 
RI and Sal I restriction endonuGleases independently, and
 
each separated on a 0.8% Tris-acetate (TAE) agarose gel
 
(figure 3). Following phenol extractioh and ethanol
 
precipitation, the pool of fragments from each enzymatic
 
reaction were randomly ligated to an alkaline phosphatase-

treated pBluescript vector KS"'", containing compatible Eco RI
 
or Sal I staggered 3' ends. The two remaining open 5'
 
phosphodiester bonds were closed in vivo after transformation
 
into the bacterial cell. White colonies were selected, and
 
screened for plasmid sizing (Figure 4). Based on differences
 
in recombinant plasmid sizes, seven recombinant clones were
 
selected and subsequently amplified. Enzymatic cleavage of
 
each selected fecqmbiriant clone with Eco RI revealed
 
potential insert sizes as well as false-positive recombinant
 
clones (Figure 5). False positive clones may result from the
 
loss of the episome ( F', pro AB, lac M15) in XL-1 blue
 
cells, coding for the B-gal omega fragment, necessary for
 
Alpha-complementation, and/or the transformation of bacterial
 
cblls with concatenate configuratiohs of the plasmid vector.
 
Recombinant clones pBS 11, 14, and 3 contain inserts of
 
approximately 1.5 kb, 2.3kb,and 5.5kb, respectively; while
 
recombinant clone pBS 7 contains no apparent chlamydial
 
insert. All seven recombinant clones (pBS-1,-3,-7,-11,-12,­
14, and -24) were grown to log phase in rich media under
 
selective conditions and IPTG-induced for 3 to 4 hours.
 
Following cell lysis by sonication and one freeze-thaw cycle,
 
the crude supernatant and pellet fractions from each clone
 
were dot blotted and screened for chlamydial immunoreactive
 
product (Figure 6). One clone (pBSl) expressed a recombinant
 
chlamydial antigen. Complete enzymatic cleavage of the pBSl
 
DNA with Eco RI originally generated two fragments (3.0 kb
 
and 2.0 kb), indicatihg a potential insert size of two
 
kilobases.
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 Figure 1. Comparison of immunoreactive signal
 
level between the supernatant and pellet fractions of
 
the recombinant product Ct-9. The cell lysate from
 
bacterial cultures infected with the recombinant CT-9 lambda
 
bacteriophage was collected, centrifuged, and the pellet and
 
supernatant fractions were dot blotted onto a nitrocellulose
 
membrane. The membrane was exposed to whole cell Ct. Serovar
 
D polyclonal antisera. Positive and negative controls
 
include immunoblots A-1 (Ct. Serovar D), and A-2 (recombinant
 
Ct-9 lambda bactiophage). Immunoblots A-3 thru A-6 contain
 
pellet fractions of the Ct-9 recombinant product, followed by
 
two-fold serial dilutions of the same preparation.
 
Immunoblots A-7 thru A-10 contain supernatant fractions of
 
the Ct-9 recombinant product, followed by two-fold serial
 
dilutions of the same preparation. Immunoblots A-11 and A-12
 
contain the recombinant Ct-9 cell suspension and a 1:2
 
dilution, respectively.
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Figure 2. Comparison yield of recombinan't gene
 
product following static or aerated incubation. Cell
 
cultures infected with Ct-9 labmda recombinant bacteriophage
 
were incubated either statically or with aeration. Despite a
 
50-fold pellet concentration, only a slight increase in
 
immunoreactive signal was obtained. Immunoblots A-1 and A-2
 
are positive and negative controls respectively. Immunoblots
 
A-5 thru A-9 contain 50-fold concentrated pellet suspensions
 
from aerated culture preparation, followed by two-fold serial
 
dilutions. Immunoblots C-10 thru D-3 contain 50-fold
 
concentrated pellet fractions from statically grown infected
 
cultures, followed by two-fold serial dilutions.
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Figure 3. DNA digestion of lambda recombinant dt-9
 
clone with EcoRI and Sail. The purified reconibinant
 
EMBL-3 DNA sample (Ct-9 clone) was cleaved with EcoRI and
 
Sail restriction endonucleases independently, and the DNA
 
fragments generated from each reaction were separated on a
 
0.8% Tris-acetate (TAE) agarose gel. Cleavage with ECoRI
 
yielded five distinct fragments of various sizes, while the
 
Sail reaction mix generated three fragments.
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Figure 4. Plasmid sizing of recombinant: pBluescript
 
clones. Potential white recombinant colonies and non-

recombinant blue colony controls were screened by the rapid
 
plasmid screen assay (see Materials and Methods). Lanes 1-14
 
contain supercoiled DNA from white recombinant colonies with
 
insetts at the EcoRI site. Lanes 15 and 30 contain DNA from
 
blue colonies (negative controls). Lanes 16-29 contain DNA
 
from recombinant colonies with inserts at the Sail site.
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Figure 5. Enzymatic cleavage of recombinant DNA
 
clone with EcoRI. Supercoiled DNA templates from potential
 
pBluescript recombinant clones were cleaved with EcoRI to
 
reveal various Ct. DNA insert sizes. Lane 1 contains uncut
 
DNA pBluescript control vector. Lane 2 contains uncut DNA
 
from recombinant clone 1 (renamed, pBSl). Lanes 3-8 contain
 
uncut pBluescript recombinant DNA clones: pBS3, pBS7, pBSll,
 
pBS12, pBS14, and pBS24 respectively. Lane 9 contains the
 
pBluescript control vector digested with EcoRI. Lane 10
 
displays the pBS24 recombinant DNA clone, containing the Sail
 
site after cleavage with EcoRI. Lanes 11-14 contain
 
recombinant pBluescript DNA clones digested with EcoRI:
 
pBS14, pBS-11, pBS-7, and pBS-3, respectively. Lane 15
 
contains recombinant DNA (Ct-9 clone) cleaved with EcoRI.
 
Lane 16 contains ICQ ng of Lambda DNA mix markers.
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Figure 6. Expression of the Recombinant Ct. product
 
(clone immunoscreening). All seven potential recombinant
 
clones were screened for immuno-reactive product. Only one
 
clone/ renamed pBSl expressed a recombinant Ct• product.
 
Immunodot A-1 is a positive control containing a whole cell
 
suspension of Ct. Serovar D. A-4 is the pBS-l pione whole
 
cell reaction mix. B-8 arid B-9 contain the 50X concentrated
 
whole cell reaction mix of clone pBSl, followed by a 1:10
 
dilution of that suspension. C-12 and D-1 contain the
 
concentrated suspension after sonication, followed by a 1:10
 
dilution. Immunodots F-4 and F-5 represent the pBSl 50X
 
lysate suspension after sonication and one freeze-thaw cycle.
 
Samples F-8 and F-9 represent the pBS-1 supernatant fraction
 
followed by a 1:10 dilution. Finally, samples G-12 and H-1
 
show the immunoreactive signal obtained from the pBS—1 pellet
 
fraction and its 1:10 dilution.
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However, further restriction:analysis of the pBSl clone DNA
 
with Hind III, and Sac I, and partial digestion with Eco RI
 
revealed the inserted Ct DNA to be approximately 5.0 Kb Ipng
 
(Figure 7a, 7b and Figure 8), suggesting the existence of an
 
Eco RI.site internal to the pBSl insert DNA.
 
pBluescript Recpmbinant Ct. Product. The pBluescript
 
vector provided higher Ct product yield and demonstrated the
 
product associatiori with the supernatant fraction of cell
 
lysates (Figure 9). The crude supernatant was analyzed by
 
size exclusion HPLC (SEC-HPLC), where the stationary phase is
 
silica based and possesses properties suitable for use with
 
aqueous buffers. The crude supernatant from clone pBSl was
 
injected into the HPLC system, and each fraction was
 
collected and tested for Ct product signal (Figure 10). It
 
was found that: 1) recovery of the recombinant product was
 
generally in excess of 90%, 2) the profile was highly
 
reproducible, and 3) the elution order was predictable. The
 
retention time (Tr) of the pBSl sample, which is the time
 
from injection to the time of maximum concentration in the
 
eluted peak, was approximately 20 minutes. Dot immunoblots
 
revealed that all the recombinant product was found in the
 
void volume (Vo). The void volume represents the sum of the
 
interstitial volume between the particles of the stationary
 
phase and the accessible volume within the particle pores.
 
Attempts to use denaturing and reducing agents such as SDS
 
and B-mercaptoetha:nol and/or organic solvents
 
(trifluoroacetic acid) to inhibit any intermolecular
 
interactions of solutes proved unsuccessful. However, a
 
significant number of molecules ranging from 10,000 - 150,000
 
daltohs were successfully removed, thus' semi-purifying the Ct
 
recombinant protein mixture.
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Identification and Comparison of the Recombinant Ct.
 
protein product derived from EMBL-3 Lambda and
 
pBluescript. The relationship between thb recombinant 
protein mixture derived from the EMBL-3 lambda and 
pBluescript vector, and the Ct serovar D whole cell 
suspension was established by SDS-PAGE and Western
 
immunoblots. The protein concentratidn for each antigen
 
preparation was determined by the BCA'protein assay (See
 
Materials and Methods). Each protein sample was diluted in
 
sample buffer to standarize the total amount of Idading
 
material to 30 ug/mm^. The molecular weight range of the Ct
 
serovar D solubilized whole cell suspensions was estimated
 
between 17,000 to 130,000 daltons. Figure 11 shows a Western
 
immunoblot of the recombinant clones and their corresponding
 
parent vectors. An immunoreactive band of approximately 36
 
kd was observed in both the bacteriophage (Ct-9) and the
 
plasmid derived (BSl) recombinant clones and in the Ct
 
serovar D antigen preparations. However, a 36kd band is
 
absent in both parent (non-insert containing) vectors, EMBL-3
 
and pBluescript.
 
Murine Immunogenic Response bo the Cb. Recombinant:
 
36kd Probein. Identification of the Ct recombinant 36kd
 
protein was followed by the preparation of the recombihant
 
lysate samples and controls for the immunization of mice to
 
test their immunogenicity. Twenty one CF-l female mice were
 
divided into seven grdups and immunized subcutaneously with
 
suspensions (0.1 ml in PBS) containing 200 ug of total
 
protein. Due to a lower protein cdncentration obtained from
 
the HPLG-purified BS-l lysate preparation, 50 ug (total
 
protein) was administered to this particular group. An
 
analysis of the sera collected from each group demonstrated
 
that all recombinant groups presented an immuhogenic response
 
to the Gt. recombinant 36kd protein.
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A soiubilizeci Ct serovar w cell euspensiori was
 
separated on a 12.5% SDS polyacrylamide gel, and
 
electrophoretically transferred onto a nitrocellulose
 
membrane. The nitrocellulose paper was then cut into strips
 
of equal length, and each strip was exposed to individual
 
serum collected from each immunized group of CF-1 mice. No
 
immunoreactive bands at the 36kd location were found in any
 
of the control groups (non-immunized mice, EMBL-3, and
 
pBluescript) (Figure 12). However, the sera from all
 
recombinant preparations (lambda Ct-9, pBluescript BS-1, and
 
.
 
HPLC-purified BS-1) demonstrated an immunoreactive band of
 
approximately 36kd. The group of mice innoculated with the
 
Ct serovar D whole cell suspension failed to present the 36kd
 
immunoreactive band, which may be due to the variable
 
frequencies of response in mice to the Ct. 36kd protein,
 
and/or an immune response below detectable levels; thus,
 
minimizing or apparently eliminating the 36kd band signal
 
from the immunoblot. Finally, to determine the putative
 
cellular location of the 36kd protein in Ct serovar D, an
 
antibody-capture enzyme immunoassay was designed; however, no
 
conclusive data was found to clearly support a putative
 
cellular location of the 36kd Ct protein by this assay.
 
Partial DNA sequencing of the Ct. Recombinant
 
gene. The Bluescript plasmid-derived Ct. recombinant gene
 
(BS-1) was partially sequenced by the dideoxy-chain
 
termination sequencing method. The T7 and T3 primers, found
 
at either side of the target insert in the multiple cloning
 
site of the pBluescript KS"^ vector, were hybridized to a
 
single stranded template, and extended by T7 DNA polymerase
 
to approximately 350 bases on either priming site. Figure
 
13 illustrates the partial DNA sequence obtained from the
 
Ct.recombinant gene. The KS and T3 sequencing reactions
 
extended the Ct recombinant DNA coding strand
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Figure 7a and 7b. Digestion of pBluescript and
 
Recombinant clone DNA pBSl with HindiII, Sad, and
 
EcoRI. In Figure 7a, lanes 1, 3, and 6 contain pBluescript
 
control DNA digested with Hindlll, Sad, and EcoRI,
 
respectively. Lanes 2, 5, and 7 display the separation
 
profile of DNA fragments obtained from the enzymatic cleavage
 
of the recombinant pBSl DNA clone with Hindlll, Sad, and
 
EcoRl, respectively. Lane 4 contains 500 ng of lambda DNA
 
molecular mix markers cut with Hindlll and EcoRI,
 
In figure 7b, lane 1 contains supercoiled pBSl DNA. Lane
 
2 contains lambda molecular mix markers, and lanes 3 and 4
 
contain the pBSl DNA cleaved with Hindlll and Sad,
 
respectively.
 
38
 
 2.0 
7a
 
1 2 3 4 5 :6 1
 
6.6 kb
 
4.2
 
3.2
 
3.i
 
2.3
 
1.57
 
0.93
 
39
 
0
0


 
L
D
 
C
O
 
L
O


 
o
o


 
0
0


 
o


 
X
i


 
C
N


 
X
­
0
0
 
A
D
 
CNJ
 
H
 
A
D


 
cSi
 
Figure 8. Partial Digestion of pBluescript vector
 
and pBSl recombinant DNA with EcoRI. Lane 1 contains
 
undigested pBluescript vector DNA; and lane 2 contains
 
pBluescript DNA partially digested with EcoRI. Lane 3
 
contains 400 ng of lambda molecular mix markers. Lane 4 and
 
lane 5 each contain DNA from clone pBSl partially,digested
 
with EcoRI and in supercoiled configuration, respectively.
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Figure Comparison of Recombinant product yield
 
obtained between the lambda Ct-9 and the pBS-1 clones.
 
Immunodots A-l and C-l contain the Ct Serovar D whole cell
 
suspension (positive controls). Negative controls are
 
represented by immunodots A-2 (lambda bacteribphage particle
 
suspension), and C-2 (pBluescript whole cell lysate
 
suspension). Immunodots; A-3 thru A-IO represent a two-fold
 
serial dilution of the pellet fraction extracted from Ct-9
 
recombinant cell lysates. Rows B-l thru B-8 represent
 
serially diluted pellet fractions from the parent lambda
 
vector EMBL-3. immunpdot C-3 contains the pBSl whole cell
 
lysate suspension. Immunodots G-4 thru D-1 contain a 2-fold
 
serial dilution of the supernatant fraction extracted from
 
the pBSl recombinant cell lysates. Finally, D-2 thru D-9
 
contain serially diluted supernatant fractions derived from
 
the parent pBluescript cell lysates.
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Figure 10. Separation Profile of Crude pBSl
 
lysate supernatant by Size-Exclusion HPLC. The
 
supernatant fraction (in IX PBS) from the pBSl lysate was
 
injected into an HPLC unit. Six chromatographic peaks were
 
minute intervals, dot blotted onto nitrocellulose membrane
 
and exposed to Ct. Serovar D whole cell antibodies,
 
(pBluescript whole cell suspension) represent positive and
 
correspond to peaks #3, #4, and #5.
 
resolved; and aliquots from all the peaks were taken at 1
 
Imirtunodot A-1 (Ct Serovar D whole cell suspension) and A-2
 
negative controls, respectively. Immunodots A-3 thru A-9
 
correspond to the void volume peak. Immunodots A-10 thru B-6
 
represent aliquots obtained under peak# 1; B-7 thru B-11
 
contain HPLC fractions from peak# 2; and B-12 thru C-12
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Figure 11. Inuaunoblot of Recombinant clones and
 
parent vectors. Lane 1 contains standard molecular weight
 
markers. Lane 2 contains the lambda recombinant clone Ct-9.
 
Lane 3 contains the pBSl plasmid Ct recombinant clone. Lane
 
4 contains the Ct. Serovar D whole cell suspension. Lane 5
 
contains the parent lambda bacteriophage (EMBL-3) or non-

insert containing vector, and lane 6 contains the pBluescript
 
parent plasmid or non-insert containing vector. Ct. serovar D
 
polyclonal antisera was used for all the antigens.
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Figure 12. Western Immunoblot of Ct. Serovar D
 
exposed to antisera from different immunized murine
 
groups. Strips of nitrocellulose membrane, containing
 
electrophoretically transferred Ct. Serovaf D antigens were
 
exposed to antisera obtained from immunized, non-immunized,
 
and control groups. Group 1 represents antisera obtained from
 
non-immunized mice. The other groups included mice immunized
 
with: a pellet suspension from the EMBL-3 lambda vector
 
(group 2), the Ct-9 lambda recombinant pellet product (group
 
3), Ct Serovar D whole cell suspension (group 4), the pBSl
 
recombinant supernatant product (group 5), the supernatant
 
fraction from the parent pBiuescript vector (group 6), and
 
the HPLC-purified pBSl recombinant product (group 7). An
 
immunoreactive band of approximately 36kd was observed in all
 
the recombinant groups. A control strip of nitrocellulose
 
membrane ("C") was exposed to Ct. Serovar D (E. coli
 
absorbed) polyclonal antisera.
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Figure 13. Partial DNA sequence of the
 
Recombinant clone pBSl with primers T3 and T7.
 
Denatured double stranded DNA clone pBSl was hybridized with
 
primers T3 or T7, and and extended by T7 DNA polymerase to
 
approximately 350 base pairs on either direction. At the
 
present time, no open reading frames or regulatory sequences
 
have been located in the pBSl clone.
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BSl /T3 Primer
 
•V,
 
10.^ 30 40 50
 
VVI::
 1 1 1 ■ V" 
CMCAGAAGG GAGAGGACTG AGTATGAGGA AGGAAATAAA TAGGAGAAGA 
GATGTCTTGC gtgtggtgtg;TGATAGTGGT TGGTTiATlT ATGGTGTTGT 
.60 ■ ■^v-'70-: V■ ^^30.■■ 
:r ■r: ■ ■ , " ^1- -3V 1 . ■ ■ ■ 
AGGAGTTeTG GTGTAGGCGT TGTTAATGGA GagGaatagg GAAATTGTGT 
tggtgaagaG GAGATGCGGA: AGAATTAGGT: GTGGTTATGG GTTTAAGAGA 7 V 
110 120 1.30. V 140 'V.. . 150V 
r,i;■ .,v ■ ■ .VI--: V-:': . ■ ■VVV7V7; ^ ^ - . :!• : ■- ■ -. l, : , .V ..V, 
ATGAAAAATA GGTAGAGAAA TTTGTGTGTA GGAGGAGGAG AAGAGTAGAG 
TAGTTTTTAT CGATGTGTtT aaagaGAgat^ ggtggi'Ggtg ttgtGatgtG 
^ ■ 1 170 "viao;- v:lM ^::■ : .V. ^■■■2.0..0 ■ 
■ ■ ■: • /I ■■ ;v. : ■ .], , .v.: 7.: . -,:^-vr- - -V. -
GTGAilAAAGA AAAAATGATG AATGGAAGGT TGGGTTGTGT ATAGGGTAAA 
GAGTATTTGT TTTTTAGTAG ttaggttgGa AGGGAAGACA TATGGGATTT 
^ 210 '220 ^V 230 V 240 ^--■■' .■:V^7.V.2S0' ■ ■ ■ ' : .■ ■ ■ 
-V-..; -: - ^ - - 'V.-V;: - .. V r v- , : .- '„ vv: . - .■ - ■■ I- . .::'^V7- -- ' ■■ .,7 v-: 
GTGGGGGGTT GGGGGTAGAA ATATGGATTA ATGTTGTTGT ATAAAAGAGG 
GAGGGGGGAA GGGGGATGTT tataggtaat taGaagaaga tatttiGtgg 7 
- 2 60 270 280 290: ■-■■ . V3.0.0" 
■ ■ ■ 1' ■ ■ ■:■ ■ ■ K V ■ ■ v' , ■ .V, 
AGAGGAATGT TTGAGGTAAG TAAGAAGAAT gaggggtagg GGAA^AAATG 
TGTGGT'TAGA AACTGGATiG ATlGTfGTTA gtGgggatgg ggttttttag ; 
■ -./r""' - ': .: ■-'3io'y v.^'32G: 330 V 7 : 340 350 
r.V.-' V-., .-.I-. 1-V:-- - - . :7 ■■ r .. . .vV-1. 
GAAGiy^AAGG TGAATGTTTA TGGATAGGTT ATTTGTTTTG TAAAAATGAG 
GTTGTTTTGG AGTTAGJy^T aggtatggaa Ti^GAAAAG atttttagtg 
■ . ■ '"■3^60' 370 i: 380
 
^ I" ■ ,7l
 
gttggtaaag ATGGGAAGGG aggaGgttgg 
GAAGGATTTG: TAGGGTTGGG TGGTGGiU^GG 
52 ' 
pBSl/ T7 Primer
 
5'-—>3'
 
10 20 30 40 50
 
I I I I
 
GAATTCTATA GTGGTTTTAG CTTTTATCGC AATCTCATTT TAGAGATTTT
 
CTTAAGATAT CACCAAAATC GAAAATAGCG TTAGAGTAAA ATCTCTAAAA
 
60 70 80 90 100
 
I I I
 
TTTGATTTGG ACAAAAGAAA ATAAAGTACT TGAGATTGTT TTCTAAGTTT
 
AAACTAAACC TGTTTTCTTT TATTTCATGA AGTCTAACAA AAGATTCAAA
 
110 120 130 140 150
 
I I
 
GTTTGCATAA ACAGCCATCA TTTATGCAGG TTAGTAGCAG AAATCTGTTT
 
CAAACGTATT TGTCGGTAGT AAATACGTCC AATCATGGTC TTTAGAGAAA
 
160 170 180 190 200
 
I I
 
GGAAGAATTT TAGTTTTGTT GAGAGTTTTT ATAGTTGTTT GGTTAGAAAA
 
GGTTGTTAAA ATGAAAAGAA GTGTGAAAAA TATGAAGAAA GGAATGTTTT
 
210 220 230 240 250
 
I I
 
GAGGTATTAG TATGGATTTT TGTTAGTTGT TAAAATTATT TAGAATGGTG
 
GTGGATAATG ATAGGTAAAA AGAATGAAGA ATTTTAATAA ATGTTAGGAG
 
260 270 280 290 300
 
I I I I I
 
TGTTGGAGAT GAGGAAGGGG GTAGATTTTG GTTTGGGTTG AGGATATAAA
 
AGAAGGTGTA GTGGTTGGGG GATGTAAAAG GAAAGGGAAG TGGTATATTT
 
310 320 330 340
 
I I I
 
TTGATTGTGT TAAAAGTATG TTTGGGATAA GGGAGGTTG
 
AAGTAAGAGA ATTTTGATAG AAAGGGTATT GGGTGGAAG
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(transcriptional orientation), while T7 and SK
 
oligonucleotides were employed to sequence the opposite or
 
non-coding DNA strand So far, no chlamydial promoter
 
regions and/or open reading frames have been found in pBS-1.
 
■ Discussion 
The essence of DNA cloning is joining a stretch of DNA of
 
interest to a vector molecule which serves to propagate that
 
DNA segment in either bacterial or eukaryotic cells. Vectors
 
for Escherlchla coli are derived from the natural phages and
 
plasmids of this organism. The use of lambda bacteriophage
 
as cloning vectors is desirable because of its ability to
 
accomodate large fragments of DNA (~ 25 kb) in its genome,
 
and its packaging into capsids in vitro (7). Depending on
 
the investigator's needs, lambda vectors may be useful either
 
as a primary or intermediate cloning step. To clone a
 
specific gene from a particular species, the usual approach
 
is to make a "library" containing some or all of the genes
 
from that species. This library consists of a population of
 
clones, each containing small segments of genetic information
 
from the species in question. Once the library has been
 
made, the next step - and usually the biggest challenge - is
 
to screen it to select the one or few clones which contain
 
the gene of interest (6). Lambda gene libraries may be
 
efficiently screened with either an antibody against the
 
protein encoded by the gene of interest (which requires some
 
part of that protein to be expressed, provided an efficient
 
promoter region is found close to the gene of interest), or a
 
labelled nucleic acid probe (which implies some knowledge of,
 
or assumption concerning the sequence being screened for).
 
In this study, however, due to low recombinant product yield
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in lambda EMBL-3, the pBluescript plasmid vector became an
 
alternative to obtain a greater yield of recombinant product
 
needed to conduct further studies.
 
The approach taken to sub-clone the lambda clone CT-9
 
expressing a 36Kd chlamydial protein into the plasmid vector
 
pBluescript is called the shot-gun method; the lambda clone
 
CT-9 (with chlamydial DNA insert) was enzymatically cleaved
 
and the pool of fragments were ligated to corresponding sites
 
on a pBluescript plasmid vector. This method requires
 
careful screening techniques to insure proper DNA
 
orientation. The first screening after bacterial
 
transformation was a rapid selection among blue and white
 
colonies to check for size variations of supercoiled plasmid
 
DNA. The DNA from both putative positive clones, and from
 
some negative clones was then isolated and cleaved with
 
restrictions enzymes to reveal respective insert sizes (refer
 
to figure 5). A second screening entailed the DNA sequencing
 
of prospective positive clones to confirm correct orientation
 
with respect to existing promoters in the pBluescript vector
 
(refer to figures 17a and 17b). A third and final screening
 
involved a dot-immunoblot and/or Western immunoblot to
 
determine the presence of the desired recombinant product.
 
False positive white colonies obtained during cell
 
transformation may result from the loss of host episomal DNA,
 
preventing the synthesis of the B-gal-omega fragment
 
necessary for alpha complementation, or the transformation of
 
bacterial cells with concatemer configurations of the plasmid
 
vector. Some white recombinant colonies apparently 
containing DNA inserts did not necessarily express a 
recombinant product when screened with Ct. serovar D 
polyclonal antibodies. Such an occurrence may be attributed
 
to several factors including: (1) the lack of an
 
immunoreactive epitope in the recombinant Ct. protein, (2)
 
the splicing of the recombinant gene coding for the 36kd
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protein, (3) the improper orientation of the recombinant gene
 
with respect to th6 promoter sequence, resulting iri either an
 
early transcrip'tional stop or wrong trahscript synthesis, and
 
(4) immunoassay conditions including the existence of epitope
 
sites hidden from reactive antibody. From all the
 
recombinant clones screened, one clone (pBSl) expressed a
 
recombinant chlamydial antigen.
 
The insert size of the pBSl clone was initially
 
determined to be 2.0 kilobases long by EcoRI cleavage.
 
However, further analysis led to the conclusion that the
 
recombinant fragment was approximately 5.0 kb long. Co-

migration of same size fragments on an agarose gel may
 
explain the visual absence of the 3.Okb chlamydial insert
 
fragment (refer to figures 8 and 9). At the protein level,
 
the pBSl recombinant product was found in the supernatant
 
fraction after the screening of plasmid-derived cell lysates.
 
The Ct product signal in dot immunodots obtained from the
 
recombinant Ct-9 clone was found to be mostly associated with
 
pellet fraction, whereas in the pBSl plasmid-derived clone
 
the recombinant product was found in the supernatant
 
fraction. A difference in location of the recombinant
 
chlamydial product relative to the membrane pellet and the
 
supernatant fraction of bacterial cell lysates in different
 
cloning vectors may be the result of the intrinsic nature of
 
each cloning system, i.e. cell lysis efficiency. Although
 
lytic infection in the parent bacteriophage lambda EMBL-3 was
 
usually a rapid process (< Ihr.) (7), leading to destruction
 
of the host cell, the recombinant bacteriophage lambda clone
 
CT-9 presented a longer incubation period (>1.5 hr.) before
 
visible lysis. Upon lysis, an infected cell culture may
 
contain free bacteriophage particles, cell membrane debris,
 
partially lysed cells, and intact cells. In effect,
 
depending on the actual rate of infection and/or lytic
 
efficiency of the recombinant bacteriophage clone, a certain
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percentage of intact cells, containing recombinant product
 
may be found in the pellet fraction, thus explaining the
 
appearance of higher signal levels in the pellet fractions of
 
dot immunoblots. A different situation is presented in a
 
plasmid vector system, where bacterial cell lysis may be
 
manipulated in a variety of ways to insure maximum cell lysis
 
efficiency.
 
The supernatant fractions from cell lysates were then
 
resolved by size exclusion HPLC. A mixture of molecules of 
different sizes is applied to a column packed with porous 
material of a specific pore size. The separation is based on 
the physical parameters of the molecules themselves; only
 
small molecules will enter the pores and slowly be passed
 
thru the column. Larger molecules will pass through the
 
column more rapidly, and thus be excluded first. Following
 
calibration of the TSK-250 size exclusion column with
 
molecular weight standards, the crude supernatant fraction
 
was injected into the system and fractions from each
 
corresponding peak were tested by dot immunoblots for the
 
presence of the chlamydial recombinant product.
 
The BSl recombinant product was found present in the void
 
volume. This indicated the possibility of either chemical
 
interactions occurring between molecules or experimental
 
parameters affecting the resolution of the solute molecules.
 
The former possibility was further tested by adding SDS, B­
mercaptoethanol, or trifluoroacetic acid to the supernatant
 
fraction to effect the separation and/or denaturation of
 
molecules before chromatographic separation. However, no
 
apparent shift in the location of the eluted product was
 
obtained. A different size exclusion column, having a
 
greater pore size, was also tried, but only a small shift in
 
the elution pattern was achieved. Despite the apparent
 
failure to effectively purify the recombinant product, a
 
variety of other molecular weight species were removed from
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the original supernatant fraction, thus yielding a semi-

purified BSl product. Relative to the Ct Serovar D whole
 
cell suspension, a 36Kd recombinant protein was identified by
 
Western immunoblots from both the lambda EMBL-3 and
 
pBluescript vectors. The immunoreactive bands thus confirmed
 
the intact transfer of the entire Ct.recombinant gene from
 
the lambda bacteriophage vector to the pBluescript plasmid
 
vector. Further, no translational fusion protein was
 
obtained from the plasmid-derived recombinant gene (17). The
 
constitutive expression of the Ct. recombinant gene in
 
E.collf in fact, suggests the presence of native regulatory
 
sequences. It was found that no apparent difference in the
 
amount of recombinant product yield was obtained from either
 
IPTG-induced or non-induced recombinant E.coll cultures (data
 
not shown), suggesting the existence of a chlamydial promoter
 
region upstream from the ribosomal binding site.
 
Alternatively, other regulative sequences compatible with the
 
E. coll (XL-1 Blue strain) enzymatic machinery may be in
 
place.
 
It has been shown (18) that a good immunogen must have
 
three chemical features: (1) it must have an epitope that can
 
be recognized by the cell-surface antibody found on B-cells,
 
(2) it must have at least one site that can be recognized
 
simultaneously by a class II protein and by a T-cell
 
receptor, and (3) usually, it must be degradable. Therefore,
 
an animal may fail to promote a good immunogenic response to
 
a given molecule if the appropriate B and/or T cells have
 
been eliminated during the development of self tolerance (15,
 
18), or if class II proteins fail to bind to the antigen
 
fragments. The lack of an antibody response due to this may
 
be overcome by modifying the antigen to add new sites for
 
class II protein binding.
 
The immunogenicity of the BSl product was evaluated,
 
following the identification of the Ct. recombinant 36 kd
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protein. immunogenicityr the ability of a molecule to induce
 
ah immune response, was determined both by the intrinsic
 
chemical structure of the injected molecule and by whether or
 
not the antigen was recognized by T and B cells (10, 18).
 
Recognition is mediated by T and B lymphocytes. B cells can
 
recognize antigens in their native conformation either free
 
in solution, on membranes, or on the surface of cells, using
 
surface immunoglobulin (Ig) as their specific antigen
 
receptor. The T cell antigen receptor (TCR) is structurally
 
different from antibody, it is generated by different sets of
 
genes and most T cells can only recognize antigen on the
 
surface of other cells (15). Specifically, T cells usually
 
recognize processed or degraded antigen, and only when it is
 
physically associated with molecules encoded by the major
 
histocompatibility complex (MHC). In effect, MHC molecules
 
act as a guidance system for T cells, allowing them to
 
recognize antigens from within cells. These three groups of
 
molecules, antibody, the TCR and MHC molecules, control the
 
process of immune recognition (15). Seven groups of CF-1
 
female mice were immunized with protein suspensions from
 
either recombinant CT-9 lambda, BSl plasmid clones, HPLC­
purifled BSl , whole cell Ct. serovar D, or appropriate
 
controls. The antisera from each group of mice were
 
collected, and reacted with strips of nitrocellulose membrane
 
containing electrophoretically transferred Ct. serovar D
 
whole cell proteins. All Ct. recombinant preparations
 
presented an immunoreactive band of approximately 36kd, while
 
all negative controls showed no immunoreactive bands at this
 
location, concluding that the recombinant product has met the
 
requirements for a good immunogen, and may fill the needs for
 
a future sub-unit vaccine.
 
An antibody capture immunoassay was used to determine the
 
cellular location of the 36kd recombinant protein (1). The
 
purified antigen was attached to a solid support (polystyrene
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plates), and antisera from each group of mice immunized with
 
the recombinant Gt protein preparatidn was allowed to bind
 
(1). The antisera V against an epitope (or more) of the Ct.
 
36kd recombinant protein was used to "probe" Ct Serovar D
 
whole cell and SDS-solubilized ocugenital isolates. After
 
washing, the amount of antibody retained on the solid support
 
was measured. No conclusive data was found to confirm the
 
cellular location of the 36 kd recombinant protein in Ct.
 
serovar D. Three factors may have affected the sensitivity
 
of the assay: (1) the amount of antigen that was bound to the
 
solid phase, (2) the avidity of the antibody for the
 
antigen, and (3) the type and number of labeled moieties used
 
to label the antibody. First, the amount of antigen that was
 
immobilized on microtiter plates was adjusted by preparing
 
dilutions 1:500 and 1:1000 which was adequate to saturate the
 
capacity of the chosen matrix, Higher levels of antigen
 
binding may have been achieved by changing the matrix to
 
nitrocellulose, which binds approximately 1000-fold more
 
protein than polystyrene plates (19). The second factor that
 
may have affected the sensitivity of the assay was the
 
avidity of the antibody for the immobilized antigen.
 
Polyclonal antisera are rich in non-specific antibodies which
 
could physically obstruct interaction of specific antibodies
 
with bound antigen. Finally, the secondary enzyme-linked
 
anti-immunoglobulin antibody was diluted 1:2000, which was
 
adequate according to standard procedure, to adjust the
 
sensitivity of detection. : In summary, despite its rapid,
 
quantitative use, an antibody capture immunoassay offered a
 
sensitivity level dependent on specific activity of antigen
 
and avidity of antisera. The use of polyclonal antisera may
 
have provided a fair signal strength and specificity, but
 
high background levels. A secondary technique (Western
 
immunoblot) confirmed immunogenicity. One of the major
 
factors that will determine the success of an enzyme
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immunoassay is the nature and amount of antigen bound to the
 
microtiter plate surface. In effect, when presented in a mix
 
pool of antigens, it is possible that the sensitivity of the
 
immunoassay may be compromised by the amount and affinity of
 
the Ct. reactive epitope in the 36kd protein to the surface
 
of the microtiter plate. All immunochemical techniques have
 
a certain background, and as the abundance of a particular
 
antigen decreases relative to the other proteins, the ability
 
of the antibodies to distinguish the correct antigen from the
 
background is reduced. This is particularly true for
 
polyclonal antibodies. In general, minor antigens will
 
always need a secondary technique to differentiate the signal
 
from the noise. Thus, any technique that allows the antigen
 
to be identified specifically among the background can be
 
used as a secondary technique. In this study, antibody
 
detection to determine immunogenicity was supplemented with a
 
secondary technique, immunoblotting (19). Western
 
immunoblotting combines the resolution of gel electrophoresis
 
with the specificity of immunochemical detection. It is a
 
particularly powerful technique for assaying the presence,
 
quantity and specificity of antibodies from different samples
 
of polyclonal antisera.
 
The likelihood of this recombinant Ct. protein becoming a
 
candidate for vaccine development depends on future
 
protection studies, where mice immunized with the Ct.
 
recombinant protein will be challenged with competent Ct.
 
serovar D suspensions. If these studies demonstrate a
 
significant level of protection, then a sub-unit vaccine may
 
be developed to study its effect on a broader range of Ct.
 
serovars. The DNA sequence analysis of the recombinant gene
 
can provide the primary amino acid sequence. Sequence
 
information can then be used to develop testable hypotheses
 
concerning the potential structure and function of this
 
molecule. The BSl recombinant gene was partially sequenced
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in this study; however, at the present time, no regulatory
 
Sequences or open reading frames have been loGated. Future
 
sequencing strategies will include the use of PCR-gene
 
walking techniques, and perhaps further enzymatic cleaveage
 
and subcloning of recombihant fragments (12). The presence
 
and sequence of a Ct. promoter compatible with the E. coll
 
host's transcriptional machinery would be highly desirable
 
given the possibility of cloning this Ct. promoter sequence
 
into a high expression vector. The likelihood of cloning
 
other low expression Ct. genes into E. coli may subsequently
 
be increased. However, other factors such as transcriptional
 
levels, and gene expression and regulation need to be 
considered. 
The potential applications of molecular genetic 
technology toward chlamydial studies are numerous. The
 
expression of unlimited quantities of chlamydial components
 
in heterologous hosts such as E. coll , provides a method of
 
obtaining sufficient quantities of these components for
 
molecular research (12). The use of recombinant DNA
 
technology plays an important role in identifying components
 
essential for pathogenesis and for induction of important
 
immune pathways. The ability to express antigenic
 
determinants that are recognized by B-cells, and others that
 
are recognized by T-cells, can be investigated in animal
 
model systems (9, 10). Molecular biological approaches
 
provide a means for construction of multiple determinants in
 
one polypeptide (22, 23). A mosaic construction that can
 
induce immunity to multiple serovars is both theoretically
 
feasible and highly desirable. With these tools, essential
 
questions may be addressed regarding the genetics of unique
 
elements of chamydial biology, immune response stimulation,
 
pathogenesis, and virulence.
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